Celldex Therapeutics, Inc (CLDX) is a publicly traded Healthcare sector company. As of May 21, 2026, CLDX trades at $31.08 with a market cap of $2.37B and a P/E ratio of -7.83. CLDX moved +2.54% today. Year to date, CLDX is +20.70%; over the trailing twelve months it is +50.81%. Its 52-week range spans $14.40 to $35.79. Analyst consensus is strong buy with an average price target of $56.73. Rallies surfaces CLDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Celldex Raises $345M and Completes Phase 3 CSU Enrollment Six Months Early: Celldex completed enrollment of 1,939 patients in its global Phase 3 CSU program six months ahead of guidance and anticipates topline data in Q4 2026 with a planned BLA submission in 2027. The company closed a follow-on public offering in April 2026, raising $345 million to fund pipeline advancement and commercialization preparations.
| Metric | Value |
|---|---|
| Price | $31.08 |
| Market Cap | $2.37B |
| P/E Ratio | -7.83 |
| EPS | $-3.90 |
| Dividend Yield | 0.00% |
| 52-Week High | $35.79 |
| 52-Week Low | $14.40 |
| Volume | 645.12K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.54M |
| Net Income | $-258.76M |
| Gross Margin | 87.06% |
12 analysts cover CLDX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $56.73.